Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis

This is the first report showing rapid improvement of the AD molecular signature with targeted anti-IL-4 receptor α therapy. These data suggest that IL-4 and IL-13 drive a complex, TH2-centered inflammatory axis in patients with AD.